DB:1WQ

Stock Analysis Report

Executive Summary

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States.


Snowflake Analysis

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Neon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1WQ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

17.2%

1WQ

-4.9%

DE Biotechs

-3.0%

DE Market


1 Year Return

-58.3%

1WQ

-12.7%

DE Biotechs

-20.6%

DE Market

Return vs Industry: 1WQ underperformed the German Biotechs industry which returned -10.6% over the past year.

Return vs Market: 1WQ underperformed the German Market which returned -20.4% over the past year.


Shareholder returns

1WQIndustryMarket
7 Day17.2%-4.9%-3.0%
30 Day44.1%-10.3%-19.1%
90 Day127.5%-22.8%-26.2%
1 Year-58.3%-58.3%-12.5%-12.7%-18.3%-20.6%
3 Yearn/a15.6%14.3%-18.8%-25.6%
5 Yearn/a-8.6%-11.0%-19.9%-30.7%

Price Volatility Vs. Market

How volatile is Neon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Neon Therapeutics undervalued compared to its fair value and its price relative to the market?

2.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 1WQ's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 1WQ's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 1WQ is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 1WQ is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1WQ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1WQ is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Neon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-9.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1WQ is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 1WQ is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 1WQ is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 1WQ's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 1WQ's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1WQ is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Neon Therapeutics performed over the past 5 years?

4.2%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 1WQ is currently unprofitable.

Growing Profit Margin: 1WQ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 1WQ's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 1WQ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 1WQ is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 1WQ has a negative Return on Equity (-271.19%), as it is currently unprofitable.


Next Steps

Financial Health

How is Neon Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1WQ's short term assets ($31.2M) exceed its short term liabilities ($10.4M).

Long Term Liabilities: 1WQ's short term assets ($31.2M) exceed its long term liabilities ($6.5M).


Debt to Equity History and Analysis

Debt Level: 1WQ is debt free.

Reducing Debt: 1WQ has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 1WQ has a high level of physical assets or inventory.

Debt Coverage by Assets: 1WQ's debt is covered by short term assets (assets are 3.5176490789484E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1WQ has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 1WQ has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.1% each year


Next Steps

Dividend

What is Neon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1WQ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1WQ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1WQ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1WQ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1WQ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Hugh O’Dowd (54yo)

3.58s

Tenure

US$2,404,325

Compensation

Mr. Hugh O’Dowd, M.B.A. serves as Director of Puma Biotechnology, Inc. since October 15, 2019. Mr. O’Dowd has been Chief Executive Officer and President of Neon Therapeutics Inc. since September 27, 2016.  ...


CEO Compensation Analysis

Compensation vs Market: Hugh's total compensation ($USD2.40M) is above average for companies of similar size in the German market ($USD427.28K).

Compensation vs Earnings: Hugh's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Hugh O’Dowd
President3.58yrsUS$2.40m1.63% $1.1m
Eric Lander
Independent Director4.5yrsUS$240.53k0.46% $318.6k
Yasir Al-Wakeel
Chief Financial Officer2.83yrsUS$1.03m0.15% $100.8k
Richard Gaynor
President of Research & Development3.42yrsUS$1.02m0.18% $120.9k
Edward Fritsch
Founder & CTOno datano datano data
James Allison
no datano datano data
Nir Hacohen
no datano datano data
Robert Schreiber
no datano datano data
Ton Schumacher
no datano datano data
Catherine Wu
no datano datano data

3.4yrs

Average Tenure

58yo

Average Age

Experienced Management: 1WQ's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Hugh O’Dowd
President3.58yrsUS$2.40m1.63% $1.1m
Eric Lander
Independent Director4.5yrsUS$240.53k0.46% $318.6k
Stephen Sherwin
Independent Director4.58yrsUS$193.56k0.16% $107.0k
Robert Tepper
Independent Director6.5yrsUS$194.67kno data
Robert Kamen
Independent Director4.58yrsUS$192.30kno data
Nina Bhardwaj
Member of Scientific Advisor Boardno datano datano data
Roy Herbst
Member of Scientific Advisor Boardno datano datano data
Cary Pfeffer
Chairman of the Board3.58yrsUS$212.01kno data
Meryl Zausner
Independent Director2.33yrsUS$196.09kno data
John Haanen
Member of Scientific Advisory Boardno datano datano data

4.5yrs

Average Tenure

62yo

Average Age

Experienced Board: 1WQ's board of directors are considered experienced (4.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 85.4%.


Top Shareholders

Company Information

Neon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neon Therapeutics, Inc.
  • Ticker: 1WQ
  • Exchange: DB
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$75.031m
  • Listing Market Cap: US$68.616m
  • Shares outstanding: 28.86m
  • Website: https://www.neontherapeutics.com

Number of Employees


Location

  • Neon Therapeutics, Inc.
  • 40 Erie Street
  • Suite 110
  • Cambridge
  • Massachusetts
  • 2139
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NTGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
1WQDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/02 22:59
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.